Detalhe da pesquisa
1.
Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion.
Cancer Immunol Immunother
; 72(12): 4001-4014, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37973660